Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00010803 · ClinicalTrials.gov registry record · Phase 3
Ginkgo Biloba Prevention Trial in Older Individuals
A Phase 3 study of Dementia and Alzheimers Disease, sponsored by National Center for Complementary and Integrative Health (NCCIH).
- Completed
- Registry status
- Phase 3
- Development phase
- 3,069
- Enrollment target
- 5
- Study locations
NCT00010803: Completed Phase 3 study of Dementia and Alzheimers Disease, sponsored by National Center for Complementary and Integrative Health (NCCIH).
NCT00010803 is a Phase 3 study of Dementia and Alzheimers Disease that has completed, run by National Center for Complementary and Integrative Health (NCCIH). The registered enrollment target is 3,069 participants, below the 7,708-participant average among 199 other Dementia trials with a reported enrollment target (60% lower). The trial reports 5 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00010803, a Phase 3 study of Dementia and Alzheimers Disease, has completed, sponsored by National Center for Complementary and Integrative Health (NCCIH).
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 3,069 participants
- Enrollment target
- 5
- Study locations
Study Summary
This study will determine the effect of 240mg/day Ginkgo biloba in decreasing the incidence of dementia and specifically Alzheimer's disease (AD), slowing cognitive decline and functional disability, reducing incidence of cardiovascular disease, and decreasing total mortality.
Primary Outcome
All cause dementia based on DSM-IV criteria as determined by an expert panel of clinicians using an adjudication process. A full neuropsychological battery was administered annually, or at 6 month visit if there was a diagnosis of dementia or initiation of medication for dementia by private physician, or change in Modified Mini Mental State Exam (3MSE), Clinical Dementia Rating (CDR), or Alzheimer Disease Assessment Scale (ADAS-Cog). Decline on tests scores based on an algorithm resulted in a ne
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Ginkgo biloba
Study Locations (5)
California
- University of California, Davis - Sacramento
Maryland
- Johns Hopkins University - Baltimore
North Carolina
- Wake Forest University School of Medicine - Winston-Salem
Pennsylvania
- University of Pittsburgh - Pittsburgh
Virginia
- University of Pittsburgh/University of Virginia - Charlottesville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,069 participants |
| Start Date | 2000-10 |
| Est. Completion | 2011-07 |
| Phase | Phase 3 |
What the finished NCT00010803 record still lists
NCT00010803 is an interventional study that assigns participants to a tested intervention. Its 3,069 participants enrollment target places it among the larger protocols in the corpus, below the 7,708-participant average among 199 other Dementia trials with a reported enrollment target (60% lower).
The record links to 2 conditions, with Dementia appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00010803 lists 5 locations in 5 states (California, Maryland, North Carolina).
Frequently Asked Questions
What is clinical trial NCT00010803 about?
NCT00010803 is a clinical study titled "Ginkgo Biloba Prevention Trial in Older Individuals". This study will determine the effect of 240mg/day Ginkgo biloba in decreasing the incidence of dementia and specifically Alzheimer's disease (AD), slowing cognitive decline and functional disability, reducing incidence of cardiovascular disease, and decreasing total mortality.
What is the current status of trial NCT00010803?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 3,069 participants. The study started on 2000-10. Estimated completion is 2011-07.
What conditions does trial NCT00010803 study?
This clinical trial studies the following conditions: Dementia, Alzheimers Disease.
What interventions are being tested in trial NCT00010803?
The interventions under investigation include: Placebo (DRUG), Ginkgo biloba (DRUG).
Who is sponsoring clinical trial NCT00010803?
This trial is sponsored by National Center for Complementary and Integrative Health (NCCIH), which has 203 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00010803 being conducted?
This trial has 5 study locations across California, Maryland, North Carolina, Pennsylvania, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dementia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00010803's enrollment target sits among peer trials
3,069 20th of 199 higher than 180 of 199 other Dementia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Dementia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
ACHIEVE Brain Health Follow-Up Study
ACTIVE NOT RECRUITING · Phase 3
-
A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (TRAILBLAZER-ALZ 6)
ACTIVE NOT RECRUITING · Phase 3
-
DIAN-TU Amyloid Removal Trial (ART) in Dominantly Inherited Alzheimer's Disease
ACTIVE NOT RECRUITING · Phase 3
-
Escitalopram for Agitation in Alzheimer's Disease
ACTIVE NOT RECRUITING · Phase 3
-
Preventing Cognitive Decline With Alternative Therapies
COMPLETED · Phase 3
-
Efficacy and Safety of Aricept in the Treatment of Severe Alzheimer's Disease
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06667700 · 3,082 participants · Phase 3
A Clinical Study of Molnupiravir to Prevent Severe Illness From Coronavirus Disease 2019 (COVID-19) in People Who Are High Risk (MK-4482-023)
- NCT05534243 · 3,090 participants · NA
The ED-AWARENESS-2 Trial
- NCT07116967 · 3,040 participants · Phase 3
Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)
- NCT04722822 · 3,100 participants · NA
The HPV 9-10 Trial: Early Initiation of HPV Vaccination
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia